Skip to Content

Armodafinil Dosage

Applies to the following strength(s): 150 mg ; 50 mg ; 200 mg ; 250 mg

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Narcolepsy

150 mg or 250 mg orally once daily in the morning

It is not clear if doses beyond 150 mg daily confer additional benefit.

Usual Adult Dose for Obstructive Sleep Apnea/Hypopnea Syndrome

150 mg or 250 mg orally once daily in the morning

It is not clear if doses beyond 150 mg daily confer additional benefit.

Usual Adult Dose for Shift Work Sleep Disorder

150 mg orally once daily one hour prior to the start of the work shift

Renal Dose Adjustments

Data not available; however, in a single (200 mg) dose modafinil study, the pharmacokinetics of modafinil were not significantly affected in patients with a creatinine clearance less than or equal to 20 mL/min. However, exposure to the inactive metabolite, modafinil acid was increased 9 fold.

Liver Dose Adjustments

In patients with severe hepatic dysfunction, the manufacturer states that armodafinil should be administered at a reduced dose; however, a specific dose has not been recommended.

In a study with patients who had liver dysfunction, the oral clearance of modafinil was decreased by about 60% and the steady state concentration was doubled compared to normal patients.

Dose Adjustments

Use of lower doses should be considered in elderly patients as clearance may be reduced as a consequence of aging.

No dosage adjustment is recommended based on gender. No differences in pharmacokinetics were observed between men and women.

Concomitant administration of potent inducers or inhibitors of CYP450 3A4 or 3A5 could alter the plasma levels of armodafinil, therefore a dose adjustment may be necessary.

A dose adjustment may be necessary if armodafinil is coadministered with potent inducers or inhibitors of CYP450 3A4 or 3A5.


Healthcare providers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness.

Although not specifically studied, the potential for abuse exists with armodafinil.

Safety and effectiveness of armodafinil have not been established in pediatric patients (less than 17 years of age). It should be noted that serious rash including Stevens-Johnson syndrome has been reported in pediatric patients given modafinil.


Data not available

Other Comments

In patients with obstructive sleep apnea/hypopnea syndrome (OSAHS), where continuous positive airway pressure (CPAP) is considered the treatment of choice, an adequate trial period of time with CPAP should be attempted prior to initiating adjunctive treatment with armodafinil. When armodafinil is used adjunctively with CPAP, a periodic assessment of CPAP compliance has been recommended.

Periodic monitoring of blood pressure, particularly in patients with hypertension, has been suggested.

In patients taking armodafinil for extended periods of time, the manufacturer recommends periodic re evaluation of usefulness.